ARTICLE | Product Development
Middle class values
Bristol-Myers' 'millamolecules' combine benefits of small and macro molecules
January 17, 2011 8:00 AM UTC
For the past year and a half, Bristol-Myers Squibb Co. has quietly in-licensed libraries of compounds that are able to interrogate protein-protein interactions within cells. The key to accessing these previously intractable targets, according to the company, is compounds that fall between small molecules and macromolecules in size.
Small molecules weigh up to 600 daltons, and macromolecules weigh more than 10,000 daltons. BMS is looking to occupy the relatively untouched space between those two classes...